LENZ Therapeutics (LENZ) Equity Average (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Equity Average data on file, last reported at $265.4 million in Q1 2026.

• Quarterly Equity Average rose 34.02% year-over-year to $265.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265.4 million (up 34.02% YoY) and the FY2025 annual result came in at $244.2 million, up 338.55% from the prior year.
• Equity Average grew to $265.4 million in Q1 2026 per LENZ's latest filing, from $239.1 million in the prior quarter.
• Across five years, Equity Average topped out at $372.7 million in Q1 2022 and bottomed at -$81.1 million in Q4 2023.
• The 5-year median for Equity Average is $199.2 million (2025), against an average of $161.4 million.
• The widest annual swing landed in 2022, when Equity Average jumped 598.61%; it then sank 155.52% in 2023.
• Tracing LENZ's Equity Average over 5 years: stood at $146.1 million in 2022, then plunged by 155.52% to -$81.1 million in 2023, then surged by 358.42% to $209.7 million in 2024, then rose by 14.05% to $239.1 million in 2025, then advanced by 10.99% to $265.4 million in 2026.
• Per Business Quant, the three latest LENZ Equity Average figures stand at $265.4 million (Q1 2026), $239.1 million (Q4 2025), and $200.1 million (Q3 2025).

Peer Comparison